Measures of Health Related quality of life in an imperfect world: a comment on Dowie by Brazier, J.E. & Fitzpatrick, R.
HEALTH ECONOMICS
Health Econ. 11: 17–19 (2002)
DOI:10.1002/hec.669
DEBATE
Measures of health-related quality of life in an imperfect world:
a comment onDowie
John Brazier*,1 and Ray Fitzpatrick2
1Sheﬃeld Health Economics Group, School of Health and Related Research, The University of Sheﬃeld, UK
2Department of Public Health, Institute of Health Sciences, University of Oxford, UK
Professor Dowie has written an interesting and
thought provoking paper on a long lasting debate
in the literature on measuring health related
quality of life. The debate between generic and
condition speciﬁc measures (CSMs) has not
progressed a great deal with time and he is
right to question a purely psychometric approach
that currently tends to focuses on eﬀect sizes.
He has also presented an interesting challenge
to the compromise solution suggested by a number
of psychometricians to adopt both types of
measure.
The paper is predicated on the apparently useful
distinction between knowledge- versus decision-
validity, but this is something of a straw man
argument. Advocates of CMSs are not interested
in knowledge-validity but are concerned with
diﬀerent types of decisions. Furthermore, produ-
cers of criteria for judging the merits of measures
(including ourselves [1,2]) do not presume it to be
an absolute question of whether a measure is
‘valid’ but hope such lists assist researchers and
other users to ﬁnd the best measure for their
purpose, such as informing clinical or resource
allocation decisions.
For patients and clinicians important informa-
tion is provided by a trial through the use of CSMs
in terms of the impact on the problem that they
bring to the doctor – i.e. proximal concerns.
Neither the patient nor the doctor are necessarily
anticipating an impact on the more distal dimen-
sions typically covered by generic measures.
Professor Dowie’s response to this narrow view
is that there may be important consequences of the
treatment that are not covered by the CSM and
consequences for co-morbidities. This is the basis
of the usual argument for using both types of
measure in trials.
Professor Dowie goes on to argue that a generic
measure ‘is intended to cover the full range of
health outcomes’ whereas the condition speciﬁc is
by deﬁnition intended to cover a narrower
range. On the basis of this distinction of intention
he argues that in most cases the GEN should
be used alone, but he accepts that there may be
circumstances where a CSM is preferable, but
that it is never preferable to use both (for
decision-making purposes). We would just like to
make a few comments about this distinction of
intention.
CSMs typically focus on fewer domain of
interest and hence may be able to ask more
questions about each domain and thereby
achieve a greater degree of reﬁnement. For
example, the EQ-5D has a large jump in
scores between perfect health and any level
of illness of 1.0–0.88 and has only two levels of
imperfect health for each dimension. However,
Professor Dowie seems sceptical as to the
empirical evidence regarding the sensitivity of
CSMs over generics. We agree there are cases
that do not support this common claim in the
psychometric literature [3], but equally there are
many where this has been found including: EQ-5D
in chronic pulmonary disease [4] and in cosmetic
surgery [5], the SF-36 in urinary incontinence [6]
and the example of urinary incontinence that he
provides [7].
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The main concern people have with generic
measures is that their domains are too far removed
from those of the patient and are often irrelevant
to the condition. Even at the level of intention it is
not clear to us that developers of generic measures
intend to cover the full range of health problems.
Developers themselves have used terms such as
‘core’ [8] or described the content of instruments as
addressing the ‘majority’ of health concerns of
people [9]. A better approach would be to conceive
of a matrix of health, where one speciﬁc generic
measure covers Sections A and B, one speciﬁc
CSM measure covers B and C and so on. The
EQ-5D, for example, does not directly assess
cognition, seeing, hearing, sleep, energy or breath-
lessness, but these are often the primary problems
of concern to patients
The choice between generic measures and CSMs
should be made primarily on the appropriateness
of the content of the instrument. Given the
increasing emphasis on patient’s views then an
obvious group to turn to for advice are those
whom we expect to beneﬁt (or suﬀer) from the
intervention, rather than impose our own views. A
researcher will also want to choose the measure (or
measures) that best covers the domains within the
resource available for the study (including the time
of patients or their proxies). This requires some
empirical consideration of the responsiveness of
the measure. Professor Dowie is right to criticise
the psychometric literature on responsiveness, that
is often driven by comparisons of eﬀect sizes.
Biggest is not always best. What is required is to
examine the ability of measures to respond to
minimally important changes as reported by
patients in health transition questions [10]. Sensi-
tivity is important since many trials are examining
small and hard to ﬁnd diﬀerences between active
treatments, particularly in the pharmaceuticals
ﬁeld.
For social decisions, it might be thought that
the case for a reliance on generic preference-
based measures is much stronger. In order to
include health related quality of life in an
economic evaluation, the only rigorous way
would be to conduct a cost utility analysis
(CUA) which requires a preference-based measure
and since only (some) generic measure are
preference-based then this would seem to rule
out all CSMs.
At a social level, the choice of appropriate
domains is more than simply a matter for patients.
Although their views will be important, there is an
additional concern with what represents an appro-
priate beneﬁt from public funds. At least in the
UK, the reluctance to fully meet patient demands
for viagra seems to be partly based on this.
Similarly debates over IVF services have been
concerned partly concerned with the appropriate-
ness of funding such services from health care
budgets. However, we would contend that most of
the health domains covered by CSMs and generics
would be regarded as within the legitimate domain
of public funding provided there was a health
related cause.
One or other type of measure may prove to be
unnecessary since it has not picked up any changes
or because the generic has been found to
adequately reﬂect the changes in the CSM. There
will be scenarios, however, where it will be
necessary to combine the two measures. Professor
Dowie is concerned with the resultant intuitive
rather analytical basis of any decision, since this
can only be done within the framework of a cost-
consequences analysis and this is not usually
regarded as a technique of economic evaluation
at all [11]. We would be more concerned by a
policy of deliberately excluding domains of health
important to patients from consideration of
economic appraisal on the grounds of analytical
inconvenience.
We agree that in the longer term the solution
will be to either improve the generic measures by
making them more sensitive and in some case
more relevant by adding dimensions. It should
also be recognised that generics vary in the
domains they cover and a more appropriate choice
of generic may solve the problem in some cases.
The HUI-III [12], for example, covers the dimen-
sions of cognition, seeing and hearing excluded by
the EQ-5D and SF-6D but not usual activities
dimension found in the EQ-5D, and neither have a
dimension for energy, such as the SF-6D [13].
Another solution in some cases may be to improve
CSMs and extend their coverage to treatment
outcomes. For social decision-making it is also
possible to estimate preference-weighted CSMs
(for example see the work of Revicki and
colleagues [14], although this raises technical
problems of combining generic and CSM prefer-
ence-based measures where the preference function
is non-additive). For the short term, clinical
researchers and health economists must work
within the domain of a considerably less than
perfect world and this may sometimes mean using
both types of measure.
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